Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small- Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study.

Slides:

Advertisements

Similar presentations

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Advertisements

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Lobe-Specific Lymph Node Dissection as a Standard Procedure in Surgery for Non– Small Cell Lung Cancer: A Propensity Score Matching Study Hiroyuki Adachi,

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer Katsuyuki Kiura,

Endoscopic ultrasound-guided fine needle aspiration and endobronchial ultrasound- guided transbronchial needle aspiration: Are two better than one in mediastinal.

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study Kaoru Kubota, MD, PhD,

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non– Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI Akito Hata,

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third- Line Chemotherapy for Small Cell Lung Cancer Satoshi Igawa, MD, PhD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Randomized Study of Endobronchial Ultrasound-Guided Transbronchial Biopsy: Thin Bronchoscopic Method versus Guide Sheath Method Masahide Oki, MD, PhD,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Skip Mediastinal Nodal Metastases in the IIIa/N2 Non-Small Cell Lung Cancer Nenad Ilic, MD, PhD, Ante Petricevic, MD, PhD, Dragan Arar, MD, Slavica Kotarac,

Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer Gyo Asai, MD, PhD, Nobuyuki.

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? John M. Varlotto,

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non- small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan.

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae Eiji Iwama, MD, PhD, Isamu Okamoto, MD, PhD, Hidetake Yabuuchi, MD, PhD,

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition.

S-1 Treatment for Chemorefractory Thymic Carcinoma

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor– Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR.

Benefits and Adverse Events Among Elderly Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: Analysis of.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

A Functional Polymorphism on Chromosome 15q25 Associated with Survival of Early Stage Non–Small-Cell Lung Cancer Guang Jin, MD, PhD, Eun Young Bae, BS,

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer:

Presentation transcript:

Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small- Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L Yoshihito Kogure, MD, Masahiko Ando, MD, Hideo Saka, MD, Yasutaka Chiba, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiro Asami, MD, Tomonori Hirashima, MD, Takashi Seto, MD, Seisuke Nagase, MD, PhD, Kojiro Otsuka, MD, PhD, Kazuhiro Yanagihara, MD, PhD, Koji Takeda, MD, Isamu Okamoto, MD, PhD, Takuya Aoki, MD, PhD, Koichi Takayama, MD, PhD, Masahiro Yamasaki, MD, PhD, Shinzo Kudoh, MD, PhD, Nobuyuki Katakami, MD, PhD, Mikinori Miyazaki, MD, PhD, Kazuhiko Nakagawa, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 6, Pages 753-758 (June 2013) DOI: 10.1097/JTO.0b013e31828b51f5 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan–Meier plots of overall survival for patients classified according to histology type as (A) Ad and Non-Ad; histologic subtype as (B) Ad, La, Sq, and others; smoking status as (C) smokers and nonsmokers; and combination of smoking status and histology as (D) Ad and nonsmoker, Ad and smoker, Non-Ad and nonsmoker, and Non-Ad and smoker. Ad, adenocarcinoma; La, large cell; Sq, squamous cell. Journal of Thoracic Oncology 2013 8, 753-758DOI: (10.1097/JTO.0b013e31828b51f5) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions